Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics

Definitions

• the subject of the present invention relates to novel antifungal medicaments. More precisely, the subject of the present invention concerns novel antifungal medicaments based on N 2 -phenylamidine derivatives and optionally at least one other synergistic antifungal agent.
• the expression antifungal medicament is understood to mean a pharmaceutical composition intended to be administered to a human being or an animal.
• N 2 -phenylamidine derivatives also constituted antifungal compounds of choice, both in human being and in animal.
• one of the main objectives of the present invention is to provide a novel antifungal medicament based on N 2 -phenylamidine derivatives.
• Another main objective of the invention is to provide a completely effective novel antifungal medicament, especially as regards its efficacy against fungi.
• Another main objective of the invention is to provide a novel fungicidal medicament synergistically combining at least one N 2 -phenylamidine derivative and at least one other compound known as having an antifungal activity in human being or in animal.
• Another main objective of the invention is to provide a novel broad-spectrum antifungal medicament.
• Another main objective of the invention is to provide a novel antifungal medicament as defined in the above objectives and which is useful in the preventive and curative treatment of fungal diseases, in particular Candida albicans and Aspergillus fumigatus infections. All these objectives, among others, have been achieved by the inventors who have had the merit of finding that N 2 -phenylamidine derivatives surprisingly and unexpectedly exhibited a very high and perennial antifungal efficacy against a broad spectrum of agents which are infectious to human being or to animal.
• the present invention which totally or partially satisfies the abovementioned objectives, therefore relates firstly to an antifungal medicament, characterized in that it comprises at least one compound of formula (I):
• R 1 is an alkyl, an alkenyl, an alkynyl, a carbocyclic or heterocyclic monovalent group, it being possible for each of these groups to be substituted, or hydrogen;
• R 2 and R 3 which may be identical or different, are any one of the groups defined for R 1 ; a cyano; an acyl; -OR a or -SR a , with R a corresponding to an alkyl, an alkenyl, an alkynyl, a carbocyclic or heterocyclic monovalent group, it being possible for each of these groups to be substituted, or R 2 and R 3 , or R 2 and R ⁇ may form together and with the atoms linking them, a ring which may be substituted;
• R 4 is an alkyl, an alkenyl, an alkynyl, a carbocyclic or heterocyclic monovalent group, it being possible for each of these groups to be substituted, a hydroxyl group; mercapto; azido; nitro; halo; cyano; unsubstituted or substituted acyl, amino; cyanato; thiocyanato; -SF5;
• R 6 is an unsubstituted or substituted carbocyclic or heterocyclic group
• -A 1 -N(R 9 )-N C(R 8 )-, -A 3 -A 1 -, -A 4 -A 3 -, -A 2 -NR 9 -, .
• X 2 O, NR 9 or a direct bond
• R 7 which are mutually identical or different, each correspond to an unsubstituted or substituted alkyl, to a cycloalkyl or a phenyl, it being possible for each of these groups to be substituted, hydrogen, a halogen, a cyano, or an acyl;
• R 8 which are mutually identical or different, each correspond to an alkyl, an alkenyl, an alkynyl, an alkoxy, an alkylthio, it being possible for each of these groups to be substituted, a carbocyclic or heterocyclic monovalent group which may be unsubstituted or substituted, or hydrogen;
• R 9 which are mutually identical or different, each correspond to an unsubstituted or substituted alkyl, to a monovalent carbocyclic or heterocyclic group which may be unsubstituted or substituted, or to an acyl; or two R 9 groups may form together, and with the atoms linking them, a 5-7-membered ring;
• alkyl or alkyl- means a linear or branched, saturated hydrocarbon radical containing from 1 to 8 carbon atoms
• alkenyl means a linear or branched hydrocarbon radical containing from 1 to 8 carbon atoms and at least one unsaturation in the form of a double bond
• alkynyl means a linear or branched hydrocarbon radical containing from 1 to 8 carbon atoms and at least one unsaturation in the form of a triple bond; • "alkoxy” means an alkyloxy radical;
• acyl means the formyl radical or an alkoxycarbonyl radical
• cycloalkyl means a saturated cyclic hydrocarbon radical containing from 3 to 8 carbon atoms
• haloalkyl or "haloalkyl-” means a linear or branched, saturated hydrocarbon radical containing from 1 to 8 carbon atoms and substituted with one or more halogen atoms, in particular fluorine, chlorine and bromine;
• aryl means one or more aromatic radicals, preferably a phenyl or a naphthyl
• heterocycle means an unsaturated or a completely or partially saturated cyclic radical containing from 3 to 8 atoms, chosen from carbon, nitrogen, sulphur and oxygen, for example, and without limitation, pyridyl, pyridinyl, quinolyl, furyl, thienyl, pyrrolyl, oxazolinyl;
• R 1 is an alkyl, an alkenyl or an alkynyl, it being possible for each of these groups to be substituted with an alkoxy, a haloalkoxy, an alkylthiol, a halogen or a phenyl unsubstituted or substituted with an alkyl, with a haloalkyl, with an alkoxy, with a haloalkoxy, with an alkylthiol or with a halogen, or hydrogen;
• R 2 and R 3 which may be identical or different and which have the same definition as that given above for R 1 or which correspond to an alkoxy, an alkoxyalkyl, a benzyloxy, a cyano or an alkylcarbonyl;
• R 5 is a group having the same definition as that given above for R 4 '
• A is a direct bond, -0-, -S-, -NR 9 -, -CHR 7 - or -O-CHR 7 -, with R 9 , when it is present, corresponding to an alkyl, an alkenyl or an alkynyl, it being possible for each of these groups to be substituted with an alkoxy, a haloalkoxy, an alkylthiol, a halogen or a phenyl unsubstituted or substituted with an alkyl, with a haloalkyl, with an alkoxyl, with a haloalkoxy, with an alkylthiol or with a halogen, or corresponds to hydrogen; and R 7 has the same definition as that given above for R 9 or represents a hydroxyl; a halogen; a cyano; an acyl; alkoxy; a haloalkoxy or an alkylthiol;
• R 2 C C 6 alkyl, preferably ethyl
• R 3 C C 6 alkyl, preferably methyl
• R 4 C C 6 alkyl, preferably methyl
• A is linked to the carbon at C of the benzyl ring M and represents-O-;
• R 6 aryl, preferably benzyl, advantageously substituted with at least one alkyl and/or with at least one halogen or at least one cyano group.
• the compounds (I) used are, inter alia:
• the antifungal medicament comprises at least one other antifungal compound (II).
• Such an antifungal compound forms part of the compounds known to persons skilled in the art and is advantageously chosen from the following families of compounds: - azoles, such as bifonazole, butoconazole, clotrimazole, eberconazole, econazole, fenticonazole, fluconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, sulconazole, terconazole, tioconazole, voriconazole, zinoconazole;
• - azoles such as bifonazole, butoconazole, clotrimazole, eberconazole, econazole, fenticonazole, fluconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, sulconazole, terconazole, tioconazole, vori
• - allylamines and benzylamines such as butenafine, naftifine, terbinafine; - thiocarbamates, such as tolnaftate;
• - candins such as caspofungin, cilofungin
• nucleoside analogues such as flucytosine
• - polyoxines and nikkomycins such as nikkomycins Z, J, pseudo J, PX, RZ, pseudo Z
• - pradimicins such as pradimicin A
• - cationic peptides taken alone or as a mixture, and their possible tautomers and salts, in particular addition salts with an acid or a base, their lipid or liposomal formulations, which are pharmaceutically acceptable.
• the mass ratio (l/ll) is defined as follows: 0.02 ⁇ l/ll ⁇ 50 preferably 0.1 ⁇ l/ll ⁇ 20 and still more preferably 0.5 ⁇ l/ll ⁇ 10.
• the compound (l)/compound (II) ratio is advantageously chosen so as to produce a synergistic effect.
• the term synergistic effect, as understood in the present text, is defined in the examples at point 2.4.
• the preferred examples of synergistic combinations according to the invention will comprise compound (I), fluconazole and/or itraconazole, and their possible tautomers and addition salts with an acid or a base, as long as these equivalents are acceptable in the human or veterinary pharmaceutical field.
• the quantity of active agents (l/ll) present in the fungicidal compositions according to the invention is between 0.5 and 99% by weight.
• the antifungal medicaments according to the invention based on at least one compound (I) and at least one compound (II) may also comprise one or more other active products.
• the antifungal medicaments according to the invention may also contain any other excipient and/or auxiliary agent useful in pharmaceutical formulations.
• these medicaments may be provided in the form of formulations for administration orally, topically, intravenously or intraperitoneally.
• the invention relates to a method for controlling curatively or preventively, human or animal pathogenic fungi, characterized in that it consists in using an antifungal medicament as defined above.
• the antifungal medicaments according to the invention usually contain from 0.5 to 99% of the combination of compound (I) and compound (II).
• the optimum dose quite obviously depends on the type of pathogenic fungus to be treated and the seriousness of the infection.
• the pathogenic fungi which are the targets of the antifungal medicament are in particular those taken as a whole comprising:
• Yet another subject of the invention relates to the use of at least one compound of formula (I) as defined above, taken alone or in combination with another antifungal compound (II), for the manufacture of an antifungal medicament.
• the antifungal compound (II) is chosen from the families of antifungal compounds defined above.
• Yet another subject of the invention relates to the use of a medicament as defined above, for the treatment of infections of fungal origin and in particular those caused by Candida albicans or Aspergillus fumigatus.
• the objective of the trials is to test the efficacy of a compound of the arylamidine type, and two antifungal compounds of the family of azoles, fluconazole and itraconazole, already commercially available. These trials are aimed, in the first instance, at comparing the antifungal activity of the arylamidine type compound, taken alone, with that of azoles. Their aim is also to demonstrate the synergistic properties of the combinations of such compounds.
• Candida albicans strains IP 48.72 ATCC
• CNCM Cultures de Microorganismes (CNCM) of the Institut Pasteur.
• the strains are cultured on Yeast Extract-Peptone-Dextrose (YEPD) agar medium comprising 0.5% yeast extract, 0.5% bactopeptone, 2% glucose and 2% agar at 30°C and in the dark.
• YEPD Yeast Extract-Peptone-Dextrose
• All these compounds were prepared in a DMSO solution at a final concentration of 100 mg/ml.
• the stock solutions are stored at -20°C up to the time of use.
• the trials are carried out in RPMI 1640 medium with no sodium bicarbonate, but with L-glutamine buffered with 0.165 mol per litre of 3-[N-morpholino]propanesulphonic acid (MOPS), enriched ( «rich») or otherwise ( «minimal») with 2% glucose.
• MOPS 3-[N-morpholino]propanesulphonic acid
• the pH of this medium is adjusted to 7.0.
• the medium is sterilized by filtration (0.22 ⁇ m) and stored at 4°C up to the time of use.
• the antifungal compounds are tested in a range of concentrations ranging from 0.026 to 100 ⁇ g of active ingredient/ml. These antifungal compounds are then diluted in RPMI 1640 medium enriched or otherwise with 2% glucose. A final DMSO concentration of 0.2% is used throughout the measurements. Each trial is carried out on a series of dilutions of antifungal compounds, in duplicate. The antifungal dilutions (0.1 ml) and the fungal inoculum (0.1 ml) are added to each of the wells of the microtitre plate. The plates are then read with a spectrophotometer (ELX 800UV Bio-Tek Instruments, Inc) at a wavelength of 590 nm.
• ELX 800UV Bio-Tek Instruments, Inc a spectrophotometer
• the optical density values are used to calculate the percentage inhibition of growth for each concentration of antifungals by comparison with the control.
• the values are then used to plot a dose-response curve and the EC 50 value is determined for each fungus and each compound with the aid of the Grafit 5.0® software (Erithacus software Ltd).
• the method which was used to measure the type of interaction existing between the antifungal compounds in the form of mixtures is the Wadley method.
• the dose-response curve for each of the compounds A and B, and for the mixture AB is constructed.
• the Wadley approach may be used to estimate the type of interaction existing between the fungal compounds, regardless of their concentration. Its reliability is not dependent on the percentage inhibition.
• the type of interaction between two compounds is given by the level of interaction (LI) which corresponds to the ratio between the expected effective concentration
• Table 1 Efficacy in vitro of compound 1.1 , of compound 11.1 and of compound II.2 used alone against Aspergillus fumigatus cultured on minimal RPM1 1640 medium (MM).
• Table 6 Evaluation in vitro of the extent of the interaction between compound 1.1 , compound 11.1 and compound II.2 using the Wadley formula against Aspergillus fumigatus and Candida albicans cultured on minimal RPMI 1640 medium (MM) and rich RPMI 1640 medium (RM).
• the level of interaction corresponds to the ratio of the expected effective concentration (EC 50e xp) to the observed effective concentration (EC 50obs ) of the mixture.
• the synergistic interaction is present when the level of interaction is greater than 1.5 (values in bold).
• the results obtained by the Wadley method show that the combination of compound 1.1 and fluconazole (compound 11.1 ) exhibits surprising synergistic effects both on Aspergillus fumigatus and on Candida albicans.
• the antifungal medicament according to the invention therefore constitutes real progress in terms of improvement of the antifungal activity compared with the references on the market.
• compound 1.2 according to the invention was tested. It is: ⁇ /- ethyl- ⁇ /-methyl- ⁇ /'-[4-(4-cyano-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=32050123

Family Applications (1)

Country Status (8)

Cited By (30)

Families Citing this family (4)

Citations (2)

Family Cites Families (4)

• 2002
  • 2002-10-24 EP EP02356210A patent/EP1413301A1/fr not_active Withdrawn
• 2003
  • 2003-10-24 AU AU2003292131A patent/AU2003292131A1/en not_active Abandoned
  • 2003-10-24 US US10/532,033 patent/US20060052459A1/en not_active Abandoned
  • 2003-10-24 WO PCT/EP2003/013335 patent/WO2004037239A1/en not_active Ceased
  • 2003-10-24 AT AT03767675T patent/ATE452630T1/de not_active IP Right Cessation
  • 2003-10-24 DE DE60330702T patent/DE60330702D1/de not_active Expired - Lifetime
  • 2003-10-24 JP JP2004546028A patent/JP4624105B2/ja not_active Expired - Fee Related
  • 2003-10-24 EP EP03767675A patent/EP1562569B1/en not_active Expired - Lifetime
  • 2003-10-24 CA CA002502433A patent/CA2502433A1/en not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events